Glioblastoma Multiforme Treatment Market Size 2024-2028 

The glioblastoma multiforme treatment market size is forecast to increase by USD 1.36 billion at a CAGR of 8.2% between 2023 and 2028. Glioblastoma multiforme (GBM) is a malignant brain tumor with significant heterogeneity, necessitating personalized treatment approaches. The market for GBM treatment is witnessing growth due to the rising incidence of this disease and increasing research and development activities. However, the adverse effects associated with current treatments, such as corticosteroids like Dexamethasone, radiation therapy, and chemotherapy using Temozolomide, remain a challenge. To address these challenges, there is a growing interest in nanoparticle-based treatments, which offer targeted drug delivery and reduced side effects. Drug classes, including EGFR inhibitors and mTOR inhibitors, are also under investigation for their potential in GBM treatment. The market is expected to experience continued innovation as researchers and pharmaceutical companies seek to improve patient outcomes and reduce the burden of current treatment regimens.

 Request Free Sample

The glioblastoma multiforme treatment market is evolving with innovative approaches, including nanoparticle-based treatment and advanced drug therapeutics. Surgical options remain crucial, often serving as the first line of defense against this aggressive CNS cancer. Immunotherapy has emerged as a promising alternative, enhancing the body's immune response to target cancer cells more effectively. Hospitals are increasingly integrating these advanced treatments, though treatment costs can be significant, impacting patient accessibility. Additionally, awareness of male and female incidence rates is vital for understanding the disease's demographics, which informs research and treatment strategies. As the landscape of glioblastoma treatment continues to change, ongoing developments in technology and therapeutic options hold hope for improved patient outcomes.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• End-user
  • Hospitals
  • Clinics
  • Ambulatory surgical centers
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period. The glioblastoma multiforme (GBM) treatment market encompasses various modalities, with hospitals, clinics, and ambulatory surgical centers being key contributors to its growth. Hospitals hold a significant share in this market due to their ability to provide intricate patient care and access to advanced treatment methods. In 2023, hospitals generated the largest revenue in the market, driven by their capacity to offer surgical interventions, radiation therapy, and chemotherapy, all integral to managing GBM. The high volume of tumor resection surgeries and the necessity for post-operative care significantly contribute to the growth of this segment. Hospitals are also equipped with multidisciplinary teams consisting of neurosurgeons, oncologists, and radiologists, ensuring a coordinated approach to patient care.

Further, immunotherapies, such as Lomustine and Carmustine Wafers, are also gaining popularity in the treatment of GBM. Non-invasive therapies are another emerging trend in the market, offering patients less invasive alternatives for managing their condition. Overall, the market is expected to witness steady growth due to the increasing prevalence of this aggressive brain tumor and the continuous development of innovative treatment options.

Get a glance at the market share of various segments Request Free Sample

The hospitals segment accounted for USD 1.04 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

In the North American region, the advanced healthcare infrastructure and the presence of numerous pharmaceutical companies specializing in cancer treatments are significantly contributing to the expansion of the glioblastoma multiforme (GBM) treatment market. Notable industry players, including Pfizer Inc., F. Hoffmann La Roche Ltd., and Merck and Co. Inc., are based in the US, thereby increasing the market's cost. Moreover, the geriatric population in North America, who are more susceptible to this disease, is a major factor fueling the growth of the regional market. According to the American Association of Neurological Surgeons, the median age at GBM diagnosis is 65 years, and the incidence of the disease increases with age.

Further, treatment modalities for GBM include surgical interventions, radiation therapy, proton therapy, diagnostic techniques, oral treatments, and parenteral treatments. These therapies aim to breach the blood-brain barrier and deliver effective treatments to combat the disease. Cancer Treatment Centers of America and MD Anderson Cancer Center are some notable institutions providing specialized care for GBM patients in the US.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Market Driver

The increasing incidence of glioblastoma multiforme is the key driver of the market. The incidence of glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, is on the rise, accounting for approximately 14% of all primary brain tumors in the United States, with over 12,000 new cases diagnosed annually. This statistic underscores the pressing need for effective treatment options for this debilitating disease. According to the Global Cancer Observatory, the incidence of brain and central nervous system cancers reached approximately 308,102 in 2020. This escalating burden of brain cancer is driving increased research and development activities, with a focus on discovering novel therapeutic approaches, such as targeted therapies and immunotherapies, to address the unmet medical needs in this area.

Further, clinical trials play a crucial role in advancing the development of new treatments for GBM, and medical tourism is becoming an increasingly popular option for patients seeking access to cutting-edge therapies and treatments not yet available in their home countries.

Market Trends

Increasing research and development activities is the upcoming trend in the market. The glioblastoma multiforme (GBM) treatment market is witnessing significant advancements due to the increasing research and development efforts aimed at creating more effective therapies for this aggressive brain cancer. Traditional treatments, such as corticosteroids like dexamethasone, radiation therapy, and chemotherapy with temozolomide, have limited success in managing GBM. Consequently, there is a growing focus on innovative treatment approaches. One such promising development is the use of personalized treatments, including the personalized cancer vaccine, DCVax-L, which employs dendritic cells to stimulate an immune response against GBM. This approach has demonstrated positive results in phase III trials, extending survival in patients with newly diagnosed or recurrent GBM.

However, another innovative strategy gaining traction is Tumor Treating Fields (TTF), which utilizes alternating electric fields to disrupt tumor cell division, offering a non-invasive treatment option. The market is expected to grow as researchers continue to explore these and other novel treatment classes to address the tumor heterogeneity that complicates effective treatment. In summary, the glioblastoma multiforme treatment landscape is evolving, with a focus on personalized treatments and non-invasive approaches to address the challenges of tumor heterogeneity and limited success with traditional treatments. The ongoing research and development efforts in this field are expected to yield new treatment options for patients.

Market Challenge

Adverse effects associated with treatments is a key challenge affecting the market growth. Glioblastoma multiforme (GBM), a malignant brain tumor and the most common type of primary central nervous system cancer, poses significant challenges in its treatment. The traditional cancer treatment market, which primarily consists of radiation therapy and chemotherapy, has faced hurdles due to the associated morbidity and toxicities. Side effects from GBM treatment are a major concern, and each set of drugs used can have distinct side effects. Factors such as treatment schedule, dose, and combination therapies can influence the type and severity of side effects experienced by patients. Novel therapies and combination therapies are gaining traction in the GBM treatment market.

For instance, targeted therapy using bevacizumab, a monoclonal antibody, has shown promise in improving survival rates and reducing side effects. This approach inhibits the formation of new blood vessels, thus starving the tumor of blood supply. By focusing on specific targets, targeted therapies can potentially minimize the impact on healthy cells, reducing side effects. In conclusion, while the goal of GBM treatment is to eliminate cancer cells, the side effects of traditional therapies have been a significant challenge. Novel therapies, such as targeted therapy using bevacizumab, offer potential solutions by focusing on specific targets and minimizing the impact on healthy cells.

The development and implementation of these therapies in the GBM treatment market will continue to be a focus for researchers and healthcare professionals.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

• Amneal Pharmaceuticals Inc.: The company offers injection solution namely Acyclovir for glioblastoma multiforme treatment.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AIVITA Biomedical Inc.
• Amgen Inc.
• Angiochem Inc.
• Arbor Pharmaceuticals LLC
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Chimerix Inc.
• DNAtrix Inc.
• F. Hoffmann La Roche Ltd.
• Karyopharm Therapeutics Inc.
• Kazia Therapeutics Ltd.
• Medicenna Therapeutics Corp.
• Merck and Co. Inc.
• Pfizer Inc.
• Sumitomo Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Glioblastoma multiforme, a malignant tumor of the central nervous system (CNS) and the most common primary brain tumor in adults, requires innovative treatment approaches due to its aggressive nature and tumor heterogeneity. The treatment market for glioblastoma multiforme encompasses various therapies, including surgical options, radiation therapy, chemotherapy, targeted therapies, immunotherapies, nanoparticle-based treatments, gene therapy, and personalized medicines. Corticosteroids, such as dexamethasone, are often used to alleviate symptoms caused by increased intracranial pressure. Radiation therapy, temozolomide, and bevacizumab are common drug classes used in glioblastoma multiforme treatment. Novel therapies, such as combination therapies, are being explored to improve treatment outcomes. Clinical guidelines recommend a multimodal approach, including surgery, radiation therapy, and chemotherapy.

Further, surgical treatment aims to remove as much of the tumor as possible, while non-invasive therapies and patient-oriented surgery are also being investigated. Hospitals, clinics, and ambulatory surgical centers offer various treatment procedures. Drug delivery methods, such as oral and parenteral treatments, are used to administer drugs that can cross the blood-brain barrier. Cancer treatment centers and clinical trials offer access to the latest treatment options. The pharmaceutical supply chain plays a crucial role in ensuring the availability and affordability of these treatments. The high cost of glioblastoma multiforme treatment and the need for advanced healthcare infrastructure pose challenges to the treatment market. Diagnostic techniques and medical tourism are also influencing the market dynamics. Overall, the market is evolving, driven by the development of new therapies and the increasing demand for personalized medicine.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch